Borderline resectable pancreatic cancer: A consensus statement by the International Study Group of Pancreatic Surgery (ISGPS)

2014/02/07 by Maximilian Bockhorn, Faik G. Uzunoglu, Faik G. Uzunoǧlu +33 · 960 citations
Medicine · #Cancer #General surgery #Inflammatory Biomarkers in Disease Prognosis #Internal medicine #Medicine #Neoadjuvant therapy #Oncology #Pancreatic and Hepatic Oncology Research #Pancreatic cancer #Pancreatitis Pathology and Treatment #Radiology #Surgery

paper · doi:10.1016/j.surg.2014.02.001

published in Surgery 155(6), 977-988 (Elsevier BV)

openalex publication_date 2014/02/07 · openalex created_date 2025/10/10 · openalex updated_date 2026/08/04

Cited by

• Peptide receptor radionuclide therapy as neoadjuvant therapy for resectable or potentially resectable pancreatic neuroendocrine neoplasms
• Periadventitial dissection of the superior mesenteric artery for locally advanced pancreatic cancer: Surgical planning with the “halo sign” and “string sign”
• Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
• Systematic Review of Resection Rates and Clinical Outcomes After FOLFIRINOX-Based Treatment in Patients with Locally Advanced Pancreatic Cancer. [europepmc]
• Identifying prognostic intratumor heterogeneity using pre- and post-radiotherapy 18F-FDG PET images for pancreatic cancer patients. [europepmc]
• Neoadjuvant Therapy of Pancreatic Cancer: Definitions and Benefits. [europepmc]
• Outcomes After Distal Pancreatectomy with Celiac Axis Resection for Pancreatic Cancer: A Pan-European Retrospective Cohort Study. [europepmc]
• Percutaneous irreversible electroporation with systemic treatment for locally advanced pancreatic adenocarcinoma. [europepmc]
• Association Between Changes in Body Composition and Neoadjuvant Treatment for Pancreatic Cancer. [europepmc]
• Margin status and long-term prognosis of primary pancreatic neuroendocrine tumor after curative resection: Results from the US Neuroendocrine Tumor Study Group. [europepmc]
• Surgery for Pancreatic Cancer after neoadjuvant treatment. [europepmc]
• Skeletal Muscle Fibrosis in Pancreatic Cancer Patients with Respect to Survival. [europepmc]
• Immunomodulatory Effect after Irreversible Electroporation in Patients with Locally Advanced Pancreatic Cancer. [europepmc]
• Collagenase Nanoparticles Enhance the Penetration of Drugs into Pancreatic Tumors. [europepmc]
• Local radicality and survival outcome of pancreatic cancer surgery. [europepmc]
• An update on treatment options for pancreatic adenocarcinoma. [europepmc]
• Serum CA19-9 Response to Neoadjuvant Therapy Predicts Tumor Size Reduction and Survival in Pancreatic Adenocarcinoma. [europepmc]
• Neoadjuvant Treatment in Patients With Resectable and Borderline Resectable Pancreatic Cancer. [europepmc]
• Vascular Resection for Pancreatic Cancer: 2019 French Recommendations Based on a Literature Review From 2008 to 6-2019. [europepmc]
• Neoadjuvant treatment for resectable pancreatic adenocarcinoma: What is the best protocol? [europepmc]
• Noninvasive Young's modulus visualization of fibrosis progression and delineation of pancreatic ductal adenocarcinoma (PDAC) tumors using Harmonic Motion Elastography (HME) in vivo . [europepmc]
• Multidisciplinary consensus statement on the clinical management of patients with pancreatic cancer. [europepmc]
• Mechanisms of drug resistance of pancreatic ductal adenocarcinoma at different levels. [europepmc]
• The Role of Imaging in Current Treatment Strategies for Pancreatic Adenocarcinoma. [europepmc]
• Non-coding RNA biomarkers in pancreatic ductal adenocarcinoma. [europepmc]
• Reshaping preoperative treatment of pancreatic cancer in the era of precision medicine. [europepmc]
• Pancreatic cancer in 2021: What you need to know to win. [europepmc]
• Pancreatic surgery outcomes: multicentre prospective snapshot study in 67 countries. [europepmc]